Par Drugs and Chemicals Ltd
PARPar Drugs and Chemicals Ltd
PAR
Price Chart
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 13.80 | 2.94 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.49 | 6.67 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Par Drugs and Chemicals provides generic drugs. The Company is engaged in the development and manufacturing of Active Pharma Ingredients (APIs) for the domestic market, as well as for exports to international markets
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 33.30 | 48.81 | 42.42 | 46.42 | 55.94 | 62.93 | 75.25 | 95.99 | 95.88 | 105.35 | ||||||||||
Raw Materials | 14.42 | 19.59 | 17.94 | 19.22 | 22.19 | 22.09 | 29.61 | 41.03 | 33.32 | 77.12 | ||||||||||
| Power & Fuel Cost | 6.21 | 8.45 | 6.94 | 8.90 | 10.70 | 9.82 | 13.49 | 17.83 | 16.40 | |||||||||||
| Employee Cost | 1.79 | 1.84 | 2.04 | 3.64 | 4.11 | 3.98 | 4.10 | 4.89 | 5.50 | |||||||||||
| Selling & Administrative Expenses | 1.72 | 3.30 | 2.81 | 1.97 | 4.58 | 5.62 | 8.22 | 9.60 | 10.16 | |||||||||||
| Operating & Other expenses | 1.94 | 7.13 | 4.67 | 4.39 | 4.81 | 3.23 | 3.40 | 4.20 | 7.44 | |||||||||||
EBITDA | 7.22 | 8.50 | 8.02 | 8.30 | 9.55 | 18.19 | 16.43 | 18.44 | 23.06 | 28.23 | ||||||||||
| Depreciation/Amortization | 2.65 | 2.82 | 3.14 | 3.04 | 2.76 | 2.82 | 3.28 | 3.23 | 3.44 | 3.57 | ||||||||||
| PBIT | 4.57 | 5.68 | 4.88 | 5.26 | 6.79 | 15.37 | 13.15 | 15.21 | 19.62 | 24.66 | ||||||||||
| Interest & Other Items | 3.57 | 2.50 | 2.33 | 1.96 | 0.79 | 0.64 | 0.45 | 0.13 | 0.11 | 0.12 | ||||||||||
| PBT | 1.00 | 3.18 | 2.55 | 3.30 | 6.00 | 14.73 | 12.70 | 15.08 | 19.51 | 24.54 | ||||||||||
| Taxes & Other Items | 0.59 | 1.34 | 1.06 | 0.78 | 1.23 | 3.11 | 3.49 | 3.75 | 5.02 | 6.28 | ||||||||||
| Net Income | 0.41 | 1.84 | 1.49 | 2.52 | 4.77 | 11.62 | 9.21 | 11.33 | 14.49 | 18.26 | ||||||||||
| EPS | 0.38 | 1.70 | 1.38 | 1.75 | 2.24 | 4.72 | 4.99 | 9.21 | 11.78 | 14.84 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 1.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.56 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Investor Presentation
Investor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Par Drugs and Chemicals Ltd | 17.40 | 2.94 | — |
| Sun Pharmaceutical Industries Ltd | 46.13 | 6.58 | 0.73% |
| Cipla Ltd | 29.21 | 4.49 | 0.87% |
| Mankind Pharma Ltd | 62.91 | 12.57 | — |
Price Comparison
Compare PAR with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateNov 22, 2021
Dividend/Share
₹1.25
Ex DateEx Date
Nov 22, 2021
Cash Dividend
Ex DateEx DateJul 10, 2020
Dividend/Share
₹1.25
Ex DateEx Date
Jul 10, 2020
Cash Dividend
Ex DateEx DateNov 22, 2019
Dividend/Share
₹1.25
Ex DateEx Date
Nov 22, 2019
Par Drugs & Chemicals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 31 December 2024 .Powered by Capital Market - Live
Par Drugs & Chemicals will hold a meeting of the Board of Directors of the Company on 2 December 2024Powered by Capital Market - Live
Net profit of Par Drugs & Chemicals rose 75.87% to Rs 8.60 crore in the quarter ended September 2024 as against Rs 4.89 crore during the previous quarter ended September 2023. Sales rose 33.87% to Rs 34.66 crore in the quarter ended September 2024 as against Rs 25.89 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales34.6625.89 34 OPM %32.9228.47 - PBDT12.407.39 68 PBT11.496.54 76 NP8.604.89 76 Powered by Capital Market - Live
Par Drugs & Chemicals will hold a meeting of the Board of Directors of the Company on 22 October 2024.Powered by Capital Market - Live
Par Drugs & Chemicals announced that the 25th Annual General Meeting (AGM) of the company will be held on 21 September 2024.Powered by Capital Market - Live
Par Drugs & Chemicals will hold a meeting of the Board of Directors of the Company on 17 August 2024.Powered by Capital Market - Live
Par Drugs & Chemicals standalone net profit rises 2.43% in the June 2024 quarter
Net profit of Par Drugs & Chemicals rose 2.43% to Rs 2.53 crore in the quarter ended June 2024 as against Rs 2.47 crore during the previous quarter ended June 2023. Sales declined 1.40% to Rs 22.61 crore in the quarter ended June 2024 as against Rs 22.93 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales22.6122.93 -1 OPM %18.7118.05 - PBDT4.284.13 4 PBT3.383.30 2 NP2.532.47 2 Powered by Capital Market - Live
Par Drugs & Chemicals standalone net profit declines 11.79% in the December 2022 quarter
Par Drugs Standalone March 2022 Net Sales at Rs 22.08 crore, up 36.2% Y-o-Y
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 15.61%, vs industry avg of 9.04%
Increasing Market Share
Over the last 5 years, market share increased from 0.02% to 0.03%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 41.88%, vs industry avg of 15.28%